Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: Probiotics, prebiotics and the low FODMAP diet

Proceedings of the Nutrition Society

Volumn 75, Issue 3, 2016, Pages 306-318

  Staudacher, Heidi M ^a   Whelan, Kevin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

FODMAP; Irritable bowel syndrome; Prebiotic; Probiotic

Indexed keywords

DISACCHARIDE; MONOSACCHARIDE; OLIGOSACCHARIDE; PLACEBO; POLYOL; PREBIOTIC AGENT; PROBIOTIC AGENT; POLYMER;

BIFIDOBACTERIACEAE; CLINICAL EFFECTIVENESS; COLON; COLON MUCOSA; CONFERENCE PAPER; DIET; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DYSBIOSIS; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LOW CARBOHYDRATE DIET; LOW FERMENTABLE OLIGOSACCHARIDE DISACCHARIDE MONOSACCHARIDE AND POLYOL DIET; MICROBIAL COMMUNITY; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; SYMPTOMATOLOGY; IRRITABLE BOWEL SYNDROME; META ANALYSIS (TOPIC); MICROBIOLOGY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIET; DISACCHARIDES; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; MONOSACCHARIDES; OBSERVATIONAL STUDIES AS TOPIC; OLIGOSACCHARIDES; POLYMERS; PREBIOTICS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959112992     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665116000021     Document Type: Conference Paper

References (120)

1. Longstreth GF, Thompson WG, Chey WD et al. (2006) Functional bowel disorders. Gastroenterology 130, 1480-1491.
2. Gunnarsson J & Simren M (2008) Efficient diagnosis of suspected functional bowel disorders. Nat Clin Pract Gastroenterol Hepatol 5, 498-507.
3. Harvey RF, Salih SY & Read AE (1983) Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1, 632-634.
4. Lovell RM & Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10, 712-721.
5. Yao X, Yang YS, Cui LH et al. (2012) Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol 27, 760-765.
6. Engsbro AL, Simren M & Bytzer P (2012) Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 35, 350-359.
7. Mearin F, Baro E, Roset M et al. (2004) Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 99, 113-121.
8. Ladabaum U, Boyd E, Zhao WK et al. (2012) Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 10, 37-45.
9. Whitehead WE, Palsson OS, Levy RR et al. (2007) Comorbidity in irritable bowel syndrome. Am J Gastroenterol 102, 2767-2776.
10. Gralnek IM, Hays RD, Kilbourne A et al. (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119, 654-660.
11. National Institute for Health and Care Excellence (NICE) (2015) Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. http://www. nice. org. uk/guidance/cg61
12. Ford AC, Moayyedi P, Lacy BE et al. (2014) American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109, s2-s26.
13. Eswaran S, Muir J & Chey WD (2013) Fiber and functional gastrointestinal disorders. Am J Gastroenterol 108, 718-727.
14. Gunnarsson J & Simren M (2009) Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 41, 788-793.
15. Spiller R (2007) Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 19 Suppl. 2, 25-31.
16. Kashyap PC, Marcobal A, Ursell LK et al. (2013) Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 144, 967-977.
17. Marshall JK, Thabane M, Garg AX, Clark WF et al. (2010) Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59, 605-611.
18. Ohman L & Simren M (2010) Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7, 163-173.
19. Matricon J, Meleine M, Gelot A et al. (2012) Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 36, 1009-1031.
20. Barbara G, Stanghellini V, De Giorgio R et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693-702.
21. Ahn JY, Lee KH, Choi CH et al. (2014) Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci 59, 1001-1011.
22. Piche T, Saint-Paul MC, Dainese R et al. (2008) Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 57, 468-473.
23. Ritchie J (1973) Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14, 125-132.
24. Hungin AP, Becher A, Cayley B et al. (2015) Irritable bowel syndrome: an integrated explanatory model for clinical practice. Neurogastroenterol Motil 27, 750-763.
25. Drossman DA, Chang L, Bellamy N et al. (2011) Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 106, 1749-1759.
26. Bradford K, Shih W, Videlock EJ, et al. (2012) Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 10, 385-390.
27. Walter J & Ley R (2011) The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 65, 411-429.
28. Backhed F, Ley RE, Sonnenburg JL et al. (2005) Host-bacterial mutualism in the human intestine. Science 307, 1915-1920.
29. Zoetendal EG, von Wright A, Vilpponen-Salmela T et al. (2002) Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68, 3401-3407.
30. Lepage P, Seksik P, Sutren M et al. (2005) Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 11, 473-480.
31. Ohman L, Tornblom H & SimrenM(2015) Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 12, 36-49.
32. Qin J, Li R, Raes J, Arumugam M et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65.
33. Arumugam M, Raes J, Pelletier E et al. (2011) Enterotypes of the human gut microbiome. Nature 473, 174-180.
34. Knights D, Ward TL, McKinlay CE et al. (2014) Rethinking enterotypes. Cell Host Microbe 16, 433-437.
35. Kannampalli P, Shaker R & Sengupta JN (2011) Colonic butyrate-algesic or analgesic? Neurogastroenterol Motil 23, 975-979.
36. Claesson MJ, Jeffery IB & Conde S (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178-184.
37. Yatsunenko T, Rey FE, Manary MJ et al. (2012) Human gut microbiome viewed across age and geography. Nature 486, 222-227.
38. Ley RE, Turnbaugh PJ, Klein S et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023.
39. Jalanka-Tuovinen J, Salonen A, Nikkila J et al. (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS ONE 6, e23035.
40. Relman DA (2012) The human microbiome: ecosystem resilience and health. Nutr Rev 70 Suppl. 1, S2-S9.
41. Schnorr SL, Candela M, Rampelli S et al. (2014) Gut microbiome of the Hadza hunter-gatherers. Nat Commun 5, 3654.
42. De Filippo C, Cavalieri D, Di Paola Met al. (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107, 14691-14696.
43. Clarke SF, Murphy EF, O'Sullivan O et al. (2014) Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63, 1913-1920.
44. David LA, Maurice CF, Carmody RN et al. (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559-563.
45. Wu GD, Chen J, Hoffmann C, et al. (2011) Linking longterm dietary patterns with gut microbial enterotypes. Science 334, 105-108.
46. Storro O, Avershina E & Rudi K (2013) Diversity of intestinal microbiota in infancy and the risk of allergic disease in childhood. Curr Opin Allergy Clin Immunol 13, 257-262.
47. Lozupone CA, Stombaugh JI, Gordon JI et al. (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489, 220-230.
48. Le Chatelier E, Nielsen T, Qin J et al. (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541-546.
49. Turnbaugh PJ, Ley RE, Mahowald MA et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031.
50. Scott KP, Antoine JM, Midtvedt T et al. (2015) Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis 26, 25877.
51. Miquel S, Martin R, Rossi O et al. (2013) Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 16, 255-261.
52. Russell DA, Ross RP, Fitzgerald GF et al. (2011) Metabolic activities and probiotic potential of bifidobacteria. Int J Food Microbiol 149, 88-105.
53. Crouzet L, Gaultier E, Del'Homme C et al. (2013) The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 25, e272-282.
54. Collins SM (2014) A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 11, 497-505.
55. Kerckhoffs AP, Samsom M, van der Rest ME et al. (2009) Lower Bifidobacteria counts in both duodenal mucosaassociated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15, 2887-2892.
56. Parkes GC, Rayment NB, Hudspith BN et al. (2012) Distinct microbial populations exist in the mucosaassociated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 24, 31-39.
57. Jeffery IB, O'Toole PW, Ohman L et al. (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997-1006.
58. Sundin J, Rangel I, Fuentes S et al. (2015) Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 41, 342-351.
59. Carroll IM, Chang YH, Park J et al. (2010) Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2, 19.
60. Matto J, Maunuksela L, Kajander K et al. (2005) Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43, 213-222.
61. Manichanh C, Eck A, Varela E et al. (2014) Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. Gut 63, 401-408.
62. Malinen E, Rinttila T, Kajander K et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J Gastroenterol 100, 373-382.
63. Jalanka-Tuovinen J, Salojarvi J, Salonen A et al. (2014) Faecal microbiota composition and host-microbe crosstalk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63, 1737-1745.
64. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792-1801.
65. Bourdu S, Dapoigny M, Chapuy E et al. (2005) Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 128, 1996-2008.
66. Tana C, Umesaki Y, Imaoka A et al. (2010) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22, 512-519.
67. Vanhoutvin SA, Troost FJ, Kilkens TO et al. (2009) The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 21, 952-e976.
68. King TS, Elia M & Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352, 1187-1189.
69. Dear KL, Elia M & Hunter JO (2005) Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 50, 758-766.
70. Hernando-Harder AC, Serra J, Azpiroz F et al. (2010) Colonic responses to gas loads in subgroups of patients with abdominal bloating. Am J Gastroenterol 105, 876-882.
71. Hill C, Guarner F, Reid G et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506-514.
72. Miller LE & Ouwehand AC (2013) Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 19, 4718-4725.
73. Dai C, Guandalini S, Zhao DH et al. (2012) Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem 362, 43-53.
74. Zeng J, Li YQ, Zuo XL et al. (2008) Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 28, 994-1002.
75. O'Mahony L, McCarthy J & Kelly P (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551.
76. Agostini S, Goubern M, Tondereau V et al. (2012) A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 24, 376-e172.
77. Bravo JA, Forsythe P, Chew MV et al. (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 108, 16050-16055.
78. Desbonnet L, Garrett L, Clarke G et al. (2010) Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neurosciencem 170, 1179-1188.
79. Messaoudi M, Lalonde R, Violle N et al. (2011) Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 105, 755-764.
80. Tillisch K, Labus J, Kilpatrick L et al. (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144, 1394-1401.
81. Ford AC, Quigley EM, Lacy BE et al. (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109, 1547-1561.
82. Moayyedi P, Quigley EM, Lacy BE et al. (2014) The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 109, 1367-1374.
83. Hungin AP, Mulligan C, Pot B et al. (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence-based international guide. Aliment Pharmacol Ther 38, 864-886.
84. McKenzie YA, Alder A, Anderson W et al. (2012) British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 25, 260-274.
85. Whelan K (2014) Editorial: the importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 109, 1563-1565.
86. Didari T, Mozaffari S, Nikfar S et al. (2015) Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol 21, 3072-3084.
87. Gibson GR, Scott KP, Rastall RA et al. (2010) Dietary prebiotics: current status and new definition. Food Sci Technol Bull, Funct Foods 7, 1-19.
88. van Loo J, Coussement P, De Leenheer L et al. (1995) On the presence of inulin and oligofructose as natural ingredients in the western diet. Crit Rev Food Sci Nutr 35, 525-552.
89. Dunn S, Datta A, Kallis S et al. (2011) Validation of a food frequency questionnaire to measure intakes of inulin and oligofructose. Eur J Clin Nutr 65, 402-408.
90. Staudacher HM, Lomer MC, Anderson JL et al. (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142, 1510-1518.
91. Hernot DC, Boileau TW, Bauer LL et al. (2009) In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem 57, 1354-1361.
92. Rao VA (2001) The prebiotic properties of oligofructose at low intake levels. Nutr Res 21, 843-848.
93. Hunter JO, Tuffnell Q & Lee AJ (1999) Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 129, 1451S-1453S.
94. Olesen M & Gudmand-Hoyer E (2000) Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 72, 1570-1575.
95. Paineau D, Payen F, Panserieu S et al. (2008) The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 99, 311-318.
96. Silk DB, Davis A, Vulevic J et al. (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29, 508-518.
97. De Palma G, Nadal I, Collado MC et al. (2009) Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr 102, 1154-1160.
98. Duncan SH, Belenguer A, Holtrop G et al. (2007) Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 73, 1073-1078.
99. Russell WR, Gratz SW, Duncan SH et al. (2011) High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93, 1062-1072.
100. Brinkworth GD, Noakes M, Clifton PM et al. (2009) Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br J Nutr 101, 1493-1502.
101. Bohn L, Storsrud S, Liljebo T et al. (2015) Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149, 1399-1407.
102. Barrett JS, Gearry RB, Muir JG et al. (2010) Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 31, 874-882.
103. Marciani L, Cox EF, Hoad CL et al. (2010) Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 138, 469-477.
104. Murray K, Wilkinson-Smith V, Hoad C et al. (2014) Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 109, 110-119.
105. Major G, Pritchard S, Murray K et al. (2015) Mechanisms underlying FODMAP-induced symptoms in patients with irritable bowel syndrome: a double-blind crossover trial using magnetic resonance imaging. Gut 64 Suppl. 1, A33.
106. OngDK, Mitchell SB, Barrett JS et al. (2010)Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25, 1366-1373.
107. Zhu Y, Zheng X, Cong Y et al. (2013) Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am J Gastroenterol 108, 1516-1525.
108. Madsen JL, Linnet J & Rumessen JJ (2006) Effect of nonabsorbed amounts of a fructose-sorbitol mixture on small intestinal transit in healthy volunteers. Dig Dis Sci 51, 147-153.
109. Major G, Krishnasamy S, Mulvenna C et al. (2015) Effect of the low FODMAP diet and oligofructose supplement on colonic volume, transit and fermentation: a double-blind randomised controlled trial using magnetic resonance imaging in healthy volunteers. Gut 64 Suppl. 1, A57.
110. Shepherd SJ, Parker FC, Muir JG et al. (2008) Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 6, 765-771.
111. Staudacher HM, Irving PM, Lomer MC et al. (2014) Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 11, 256-266.
112. Rao SS, Yu S & Fedewa A (2015) Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 41, 1256-1270.
113. Marsh A, Eslick EM & Eslick GD (2015) Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr (Epublication ahead of print version).
114. Staudacher HM, Whelan K, Irving PMI et al. (2011) Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 24, 487-495.
115. Halmos EP, Power VA, Shepherd SJ et al. (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146, 67-75. e65.
116. Pedersen N, Andersen NN, Vegh Z et al. (2014) Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 20, 16215-16226.
117. Whelan K, Judd PA, Preedy VR et al. (2005) Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr 135, 1896-1902.
118. Chumpitazi BP, Hollister EB, Oezguen N et al. (2014) Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. Gut Microbes 5, 165-175.
119. Chumpitazi BP, Cope JL, Hollister EB et al. (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42, 418-427.
120. Halmos EP, Christophersen CT, Bird AR et al. (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64, 93-100.